Development
Bristol-Myers Squibb Company
BMY
$48.44
$0.631.32%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 26.84% | 24.08% | 20.34% | 16.96% | -9.54% |
| Total Depreciation and Amortization | -4.99% | -6.43% | -5.41% | -5.47% | -4.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.73% | -29.42% | -524.04% | -517.85% | -364.31% |
| Change in Net Operating Assets | 14.13% | -76.34% | -149.37% | -171.63% | -76.76% |
| Cash from Operations | 6.08% | -6.54% | -23.03% | -24.52% | -19.38% |
| Capital Expenditure | -8.14% | -12.18% | -1.35% | -8.55% | -14.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 72.73% | 83.71% | -71.81% | -94.45% | -166.21% |
| Divestitures | -30.34% | 78.63% | 83.09% | 76.60% | 74.47% |
| Other Investing Activities | -127.20% | -70.59% | 16.46% | 17.06% | 134.16% |
| Cash from Investing | -116.10% | 114.09% | -82.96% | -355.67% | -97.40% |
| Total Debt Issued | -27.21% | -93.83% | -94.93% | -95.31% | -- |
| Total Debt Repaid | 65.02% | 83.72% | 48.87% | 0.88% | -84.91% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 35.57% | 9.18% | 49.78% | 65.82% | -27.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.37% | -3.07% | -3.71% | -3.85% | -5.41% |
| Other Financing Activities | -97.26% | -77.43% | -79.58% | -30.30% | 53.51% |
| Cash from Financing | 44.49% | 22.93% | 12.79% | 1.53% | -4.55% |
| Foreign Exchange rate Adjustments | 236.36% | 134.07% | 123.61% | 47.27% | 67.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.96% | 93.43% | -480.09% | -380.68% | -659.67% |